Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
These proteins are tyrosine kinases involved in signal transduction cascades that regulate cell growth, proliferation, survival, and mobility. BCR-ABL1 is a fusion protein created by chromosomal translocation in leukemia, leading to constitutive kinase activity and uncontrolled cell division. c-KIT, EPHA2, and PDGFRβ are receptor tyrosine kinases activated by their respective ligands, involved in development, cancer progression, angiogenesis, and more. SRC family kinases are non-receptor tyrosine kinases that act as signaling mediators downstream of various receptors, integrating signals from growth factors, cell adhesion molecules, and immune receptors. In oncology, all are critical as drug targets due to their roles in driving malignancy upon dysregulation.
Inhibition of tyrosine kinase activity: competitive inhibition at the ATP-binding site or allosteric inhibition (asciminib for BCR-ABL1); Blockade of downstream signaling: preventing cell proliferation and survival; Induction of apoptosis in target cells
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Composite: BCR-ABL1, SRC family kinase, c-KIT, EPHA2, PDGFRβ (BCR-ABL1, SRC, KIT, EPHA2, PDGFRB).